The continual reassessment method: comparison of Bayesian stopping rules for dose-ranging studies.
about
Dose-finding design using mixed-effect proportional odds model for longitudinal graded toxicity data in phase I oncology clinical trials.Dose finding with longitudinal data: simpler models, richer outcomes.Validation of an automated safety surveillance system with prospective, randomized trial dataGood clinical activity and favorable toxicity profile of once weekly bortezomib, fotemustine, and dexamethasone (B-MuD) for the treatment of relapsed multiple myeloma.Application of hematological toxicity modeling in clinical development of abexinostat (S-78454, PCI-24781), a new histone deacetylase inhibitor.Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi.Choice of designs and doses for early phase trials.Effective dose of nefopam in 80% of patients (ED80): a study using the continual reassessment methodA phase I dose-finding and pharmacokinetic study of subcutaneous semisynthetic homoharringtonine (ssHHT) in patients with advanced acute myeloid leukaemia.Phase I studies of chemotherapeutic agents in cancer patients: a review of the designs.Principles of dose finding studies in cancer: a comparison of trial designs.Dose-finding designs using a novel quasi-continuous endpoint for multiple toxicitiesStatistical designs for early phases of cancer clinical trials.Adaptive designs for dual-agent phase I dose-escalation studies.Response-adaptive clinical trials: case studies in the medical literature.Small-sample behavior of novel phase I cancer trial designs.A comprehensive comparison of the continual reassessment method to the standard 3 + 3 dose escalation scheme in Phase I dose-finding studies.Bayesian adaptive designs in single ascending dose trials in healthy volunteers.Proportional odds model for dose-finding clinical trial designs with ordinal toxicity grading.Phase I (or phase II) dose-ranging clinical trials: proposal of a two-stage Bayesian design.Dose-finding study of ibuprofen in patent ductus arteriosus using the continual reassessment method.Minimum effective dose of midazolam for sedation of mechanically ventilated neonates.Using the continual reassessment method to estimate the minimum effective dose in phase II dose-finding studies: a case study.Application of New Designs in Phase I TrialsApplication of New Designs in Phase I TrialsApplication of New Designs in Phase I TrialsThe continual reassessment method for dose-finding studies: a tutorialHematopoietic progenitor cell mobilization and harvesting in children with malignancies: do the advantages of pegfilgrastim really translate into clinical benefit?Autologous bone marrow transplantation in the treatment of refractory systemic sclerosis: early results from a French multicentre phase I-II studyNumber of Patients per Cohort and Sample Size Considerations Using Dose Escalation with Overdose Control
P2860
Q30665810-84A46B8C-B54E-4B1B-B11C-537C1EDE1D49Q30976631-6F78B4E9-8A14-4777-9A17-FABCB4CE3789Q33385061-544B02D3-D4FD-41C1-9F00-1A6EF1D7992EQ33404749-C7A6988E-5A1B-4B5D-A7B6-2875D3E54B38Q33408198-2604FB9A-2BE2-4879-8D7C-BD3597DF5AC6Q33408772-C763CED1-C974-4EB7-883D-F603565641AFQ35775310-7DE4D534-D394-4CCC-A873-550BFAC4496FQ36388111-CEF0E13F-7DAA-4975-B105-96AD1D042FDFQ36612188-2A662FB9-2F64-4B82-A1A9-2B9878414099Q36621961-FFFD2A47-DD29-433A-8D50-47362E1E21A1Q36795347-B4E22242-D0E7-461F-A2F1-9B8776799B30Q37270128-66DBEBF2-49FA-4B1C-AC2A-4E8B85528BADQ38052915-85C0312C-433C-4C76-B754-4885E56F2138Q38090897-D243A86E-245D-425D-A70B-1C52B3FFC373Q39300281-1D2E856C-0453-4435-B62F-82AF67D01A70Q39479987-7609EC26-422C-4682-91F7-F946F7BC7BF1Q41790792-3468770C-41CF-4497-802B-4EE40328B957Q41827277-8E6EA0A3-92D0-4670-94E0-E589576AA829Q42031348-05B50C9C-F448-4BC1-ADFF-968553E671EDQ44361082-682F31E7-7A7E-4E30-82B7-CB265842B95EQ46422692-19C55282-EE5C-4696-AD4D-1D380F3EF275Q46704742-6E85E202-0471-4F8A-98FB-4F57A5AD4F02Q51541408-58D4ECC5-C527-460F-B829-2054A4B29AD8Q57338824-84691876-261E-48C4-8295-7584252AD3EBQ57338825-CC0754F5-8CD3-4238-92B4-3643F5D35433Q57338826-E8DFAE8A-DA85-4B9B-AA58-87DAA768BCB7Q57338843-3EE985EE-FCB8-43D2-88F3-EB7A76CD12D3Q58416012-4B7CF60D-E1B0-4D32-B8BF-0E55915A3547Q58416201-AC42F235-1675-4F66-B8DC-F113E286EFF5Q58910979-FEA2D48C-1123-4253-84F7-F24E6A2FFDC5
P2860
The continual reassessment method: comparison of Bayesian stopping rules for dose-ranging studies.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
The continual reassessment met ...... ules for dose-ranging studies.
@en
The continual reassessment met ...... ules for dose-ranging studies.
@nl
type
label
The continual reassessment met ...... ules for dose-ranging studies.
@en
The continual reassessment met ...... ules for dose-ranging studies.
@nl
prefLabel
The continual reassessment met ...... ules for dose-ranging studies.
@en
The continual reassessment met ...... ules for dose-ranging studies.
@nl
P2860
P356
P1476
The continual reassessment met ...... ules for dose-ranging studies.
@en
P2093
P2860
P304
P356
10.1002/SIM.920
P407
P577
2001-10-01T00:00:00Z